AETERNA ZENTARIS INC (AEZS) Stock Price & Overview
NASDAQ:AEZS • CA0079756007
Current stock price
The current stock price of AEZS is 5.72 USD. Today AEZS is up by 5.93%. In the past month the price decreased by -16.86%. In the past year, price decreased by -51.69%.
AEZS Key Statistics
- Market Cap
- 17.513M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -11.00
- Dividend Yield
- N/A
AEZS Stock Performance
AEZS Stock Chart
AEZS Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to AEZS. When comparing the yearly performance of all stocks, AEZS is a bad performer in the overall market: 91.85% of all stocks are doing better.
AEZS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AEZS. AEZS has a bad profitability rating. Also its financial health evaluation is rather negative.
AEZS Earnings
AEZS Forecast & Estimates
For the next year, analysts expect an EPS growth of 68.75% and a revenue growth -2.27% for AEZS
AEZS Groups
Sector & Classification
AEZS Financial Highlights
Over the last trailing twelve months AEZS reported a non-GAAP Earnings per Share(EPS) of -11. The EPS decreased by -274.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.8% | ||
| ROE | -139.22% | ||
| Debt/Equity | 0.01 |
AEZS Ownership
AEZS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.81 | 364.65B | ||
| AMGN | AMGEN INC | 15.23 | 188.631B | ||
| GILD | GILEAD SCIENCES INC | 15.7 | 175.177B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.61 | 116.358B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.79 | 77.963B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.93 | 41.258B | ||
| INSM | INSMED INC | N/A | 31.039B | ||
| NTRA | NATERA INC | N/A | 28.733B | ||
| BIIB | BIOGEN INC | 11.3 | 26.917B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.56 | 23.098B | ||
| MRNA | MODERNA INC | N/A | 20.683B | ||
| EXAS | EXACT SCIENCES CORP | 345.29 | 19.837B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.676B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AEZS
Company Profile
Aeterna Zentaris Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The firm is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The firm's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources, which are used in cosmeceutical products, such as oat beta glucan and avenanthramides, and is being developed as potential nutraceuticals and/or pharmaceuticals. Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-1.
Company Info
IPO: 1995-12-19
AETERNA ZENTARIS INC
C/O Norton Rose Fulbright Canada Llp, 222 Bay Street, Suite 3000, Po Box 53
TORONTO ONTARIO 29486 CA
CEO: Paulini Klaus
Employees: 21
Phone: 18439003201
AETERNA ZENTARIS INC / AEZS FAQ
What does AEZS do?
Aeterna Zentaris Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The firm is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The firm's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources, which are used in cosmeceutical products, such as oat beta glucan and avenanthramides, and is being developed as potential nutraceuticals and/or pharmaceuticals. Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-1.
Can you provide the latest stock price for AETERNA ZENTARIS INC?
The current stock price of AEZS is 5.72 USD. The price increased by 5.93% in the last trading session.
What is the dividend status of AETERNA ZENTARIS INC?
AEZS does not pay a dividend.
What is the ChartMill rating of AETERNA ZENTARIS INC stock?
AEZS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is AETERNA ZENTARIS INC (AEZS) stock traded?
AEZS stock is listed on the Nasdaq exchange.
Is AETERNA ZENTARIS INC (AEZS) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AEZS.
Who owns AETERNA ZENTARIS INC?
You can find the ownership structure of AETERNA ZENTARIS INC (AEZS) on the Ownership tab.